Trial Profile

Clinical study of SANA-013 for the treatment of Traumatic Brain Injury related major depressive disorder

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SANA-013 (Primary)
Indications Traumatic brain injuries
Focus Adverse reactions
Sponsors Wesana Health

Most Recent Events

18 Apr 2022 According to a Wesana Health media release, the company expect to initiate this study in Q4 of 2022.
18 Mar 2022 New trial record
14 Mar 2022 According to a Wesana Health media release, The Company received positive written responses from the FDA on March 11th outlining the requirements to open the IND and commence with clinical studies for SANA-013

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com